Respiratory therapy

Aviv Clinics open in Dubai, offers Hyperbaric Therapy for Fibromyalgia Treatment

Retrieved on: 
Wednesday, June 30, 2021
Health sciences, Medicine, Clinical medicine, Diving medicine, Oxygen, Respiratory therapy, Fibromyalgia, Rheumatology, Hyperbaric medicine, Diving chamber, Therapy

DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.

Key Points: 
  • DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.
  • The clinic plans to offer Hyperbaric Therapy and combat the Fibromyalgia Syndrome (FMS) condition in the country.
  • Although not hereditary, Fibromyalgia still develops at a frequent pace from environmental stimuli such as diseases, significant injury, or psychosocial circumstances.
  • To know more about Aviv Clinics and their new Hyperbaric Chamber Therapy treatment, visit their website at https://aviv-clinics.ae/ .

Aviv Clinics open in Dubai, offers Hyperbaric Therapy for Fibromyalgia Treatment

Retrieved on: 
Wednesday, June 30, 2021
Health sciences, Medicine, Clinical medicine, Diving medicine, Oxygen, Respiratory therapy, Fibromyalgia, Rheumatology, Hyperbaric medicine, Diving chamber, Therapy

DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.

Key Points: 
  • DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.
  • The clinic plans to offer Hyperbaric Therapy and combat the Fibromyalgia Syndrome (FMS) condition in the country.
  • Although not hereditary, Fibromyalgia still develops at a frequent pace from environmental stimuli such as diseases, significant injury, or psychosocial circumstances.
  • To know more about Aviv Clinics and their new Hyperbaric Chamber Therapy treatment, visit their website at https://aviv-clinics.ae/ .

Vyaire Medical Expands Ability to Streamline Respiratory Care Through Portable Remote Monitoring and Connectivity Capabilities

Retrieved on: 
Monday, June 28, 2021
Respiratory therapy, Mechanical ventilation

In addition, Vyaire Messenger will proactively notify clinicians should a patient experience a change in ventilation therapy, simplifying processes and prioritizing patients who need the most care.

Key Points: 
  • In addition, Vyaire Messenger will proactively notify clinicians should a patient experience a change in ventilation therapy, simplifying processes and prioritizing patients who need the most care.
  • "Vyaire is leveraging digital and connectivity technology to reimagine the needs of our customer base," said Gaurav Agarwal, chief executive officer of Vyaire.
  • Vyaire Messenger works seamlessly with the bellavista and Avea ventilation platforms via the Respiratory Knowledge Portal, a data application system released by Vyaire in 2015.
  • Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Global Digital Dose Inhalers Market to Reach $4.9 Billion by 2026

Retrieved on: 
Friday, June 25, 2021
Health sciences, Asthma, Dosage forms, Health care, Inhaler, Respiratory therapy, Health

SAN FRANCISCO, June 25, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Dose Inhalers - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 25, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Dose Inhalers - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Digital Dose Inhalers estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$4.9 Billion by 2026, growing at a CAGR of 13.1% over the analysis period.
  • This segment currently accounts for a 35.7% share of the global Digital Dose Inhalers market.
  • The U.S. Market is Estimated at $1.1 Billion in 2021, While China is Forecast to Reach $418.2 Million by 2026
    The Digital Dose Inhalers market in the U.S. is estimated at US$1.1 Million in the year 2021.

National Heart, Lung, and Blood Institute Turns to the Crowd for More Options in Supplemental Oxygen Technology

Retrieved on: 
Thursday, June 24, 2021
Chemistry, Physical sciences, Chemical elements, Oxygen, Diving medicine, Industrial gases, Medical equipment, Respiratory therapy, Oxygen therapy, Portable oxygen concentrator, Breathing, National Heart, Lung, and Blood Institute

The Challenge seeks to develop more portable, easy-to-use options for outpatients on supplemental oxygen.

Key Points: 
  • The Challenge seeks to develop more portable, easy-to-use options for outpatients on supplemental oxygen.
  • Yet current options for the use of home oxygen do not fully address the needs of people who rely on this resource.
  • "The demographic of those needing supplemental oxygen is much broader than many people may think," said Josh Fessel, MD, PhD, Program Director at the NHLBI.
  • They might need long-term supplemental oxygen because they're living with chronic lung disease, a heart condition, or sleep-related breathing issues.

Europe Portable Oxygen Concentrators Market Report 2020-2027 - Covid-19 Impact and Analysis by Continuous Flow, Pulse Flow, COPD, Asthma, Respiratory Distress Syndrome - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Medical devices, Health, Chemistry, Medicine, Physical sciences, Oxygen, Industrial gases, Respiratory therapy, Medical equipment, Chronic lower respiratory diseases, Oxygen concentrator, Oxygen therapy, Chronic obstructive pulmonary disease, Asthma

The Europe portable oxygen concentrators market is projected to reach US$ 710.25 million by 2027 from US$ 381.70 million in 2019.

Key Points: 
  • The Europe portable oxygen concentrators market is projected to reach US$ 710.25 million by 2027 from US$ 381.70 million in 2019.
  • The growth of the Europe portable oxygen concentrators market is attributed to the growing prevalence of respiratory disorders, rise in geriatric population and increasing demand for the portable oxygen concentrators as alternative breathing equipment amidst the COVID-19 pandemic.
  • The Europe portable oxygen concentrators market, based on product, is further segmented into continuous flow and pulse flow.
  • The Europe portable oxygen concentrators market, based on application, is segmented into COPD, asthma, respiratory distress syndrome and others.

Claire’s Place Foundation Partners with Woojer to Launch SICK BEATS

Retrieved on: 
Monday, June 21, 2021
Airway clearance therapy, Respiratory therapy, Waistcoat, 2nd millennium, Clothing, Western culture

Claires Place Foundation teamed up with Woojer to provide children from their CF community an opportunity to participate in an in-home experience trial with the vest.

Key Points: 
  • Claires Place Foundation teamed up with Woojer to provide children from their CF community an opportunity to participate in an in-home experience trial with the vest.
  • When she was 4 years old, we were able to start using the Hill-Rom vest that weighed about 15 pounds, said Claires Place Foundation Executive Director Melissa Yeager.
  • Thats why we are thrilled to partner with Woojer to finally advance airway clearance therapy with the SICK BEATS vest.
  • Today, Claires Place Foundation continues to carry on Claires legacy.

Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®

Retrieved on: 
Tuesday, June 22, 2021
Drugs, Combination drugs, Health care, Muscarinic antagonists, Indacaterol/glycopyrronium bromide/mometasone, Indacaterol/mometasone, Chronic lower respiratory diseases, Respiratory therapy, Asthma

"The commercial launch of Enerzair Breezhaler and Atectura Breezhaler is a key milestone for Valeo.

Key Points: 
  • "The commercial launch of Enerzair Breezhaler and Atectura Breezhaler is a key milestone for Valeo.
  • Commenting on the Enerzair Breezhaler and Atectura Breezhaler commercial launch, Frederic Fasano, President and Chief Operating Officer said; "We are very excited to start promoting and selling our first respiratory products.
  • Nelly Komari, a seasoned pharma executive, has recently joined Valeo to lead the medical team in support of our asthma product launches.
  • Enerzair Breezhaler and Atectura Breezhaler have demonstrated, against the current standard of care, that they improve the level of control of asthma symptoms and better prevent the related complications.

Malaysia Permission Granted for COVID-19 Test Kit from China for Emergency Use; Homegrown Holista Colltech Receives Initial Order for 15,000 Units for Deployment

Retrieved on: 
Friday, June 18, 2021
Medicine, Branches of biology, Natural sciences, Immunologic tests, Medical tests, Nasopharyngeal swab, Respiratory therapy, Rapid antigen test

With this approval, the Company has secured an initial order for 15,000 units in Malaysia.

Key Points: 
  • With this approval, the Company has secured an initial order for 15,000 units in Malaysia.
  • MOH's Medical Devices Authority ("MDA") has granted Holista permission to import and distribute up to 45,000 units of the Hecin antigen test kit for emergency use within three months from the date of approval on 14th June 2021.
  • The clinical performance of Hecin RTK-Antigen test kit against PCR Comparator method using nasopharyngeal swabs specimens has obtained a sensitivity of 96.23% and specificity 99.07%.
  • Holista CollTech Ltd ("Holista") is a natural wellness company with the following divisions:

Less Than Half of U.S. Patients With Severe Asthma Seek Care From a Specialist

Retrieved on: 
Thursday, June 17, 2021
Medical specialties, Medicine, Clinical medicine, Respiratory diseases, Asthma, Respiratory therapy, American Academy of Allergy, Asthma, and Immunology, Allergy, Stephen Holgate, Soy allergy

The 2007 guidelines of the U.S. National Heart, Lung, and Blood Institute recommend patients with severe asthma are referred to a specialist for both assessment and co-management.

Key Points: 
  • The 2007 guidelines of the U.S. National Heart, Lung, and Blood Institute recommend patients with severe asthma are referred to a specialist for both assessment and co-management.
  • "Specialist care is important for managing any condition, especially a chronic one such as severe asthma.
  • Patients with non-respiratory comorbidities, those 65 and older, and male patients were less likely to seek specialist care.
  • April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
    SOURCE The American Academy of Allergy, Asthma & Immunology